FDA OKs Mylan's generic migraine tablets

01/3/2013 | Pharmaceutical Business Review Online

Mylan Pharmaceuticals has won FDA approval for its rizatriptan benzoate orally disintegrating tablets and rizatriptan benzoate tablets to address migraine with or without aura in adults. The drugs are generic formulations of Merck's Maxalt MLT and Maxalt.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA